284 related articles for article (PubMed ID: 14962584)
1. Impact of solid state properties on developability assessment of drug candidates.
Huang LF; Tong WQ
Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
[TBL] [Abstract][Full Text] [Related]
2. High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids.
Morissette SL; Almarsson O; Peterson ML; Remenar JF; Read MJ; Lemmo AV; Ellis S; Cima MJ; Gardner CR
Adv Drug Deliv Rev; 2004 Feb; 56(3):275-300. PubMed ID: 14962582
[TBL] [Abstract][Full Text] [Related]
3. Comparison of a rational vs. high throughput approach for rapid salt screening and selection.
Collman BM; Miller JM; Seadeek C; Stambek JA; Blackburn AC
Drug Dev Ind Pharm; 2013 Jan; 39(1):29-38. PubMed ID: 22380522
[TBL] [Abstract][Full Text] [Related]
4. Compound selection for development - is salt formation the ultimate answer? Experiences with an extended concept of the "100mg approach".
Korn C; Balbach S
Eur J Pharm Sci; 2014 Jun; 57():257-63. PubMed ID: 24036162
[TBL] [Abstract][Full Text] [Related]
5. Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering.
Loschen C; Klamt A
J Pharm Pharmacol; 2015 Jun; 67(6):803-11. PubMed ID: 25851032
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of salt screening methodologies.
Fernández Casares A; Nap WM; Ten Figás G; Huizenga P; Groot R; Hoffmann M
J Pharm Pharmacol; 2015 Jun; 67(6):812-22. PubMed ID: 25683791
[TBL] [Abstract][Full Text] [Related]
7. Characterization of pharmaceutically relevant materials at the solid state employing chemometrics methods.
Calvo NL; Maggio RM; Kaufman TS
J Pharm Biomed Anal; 2018 Jan; 147():538-564. PubMed ID: 28666554
[TBL] [Abstract][Full Text] [Related]
8. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
Elder DP; Patterson JE; Holm R
J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
[TBL] [Abstract][Full Text] [Related]
9. Measurement and Accurate Interpretation of the Solubility of Pharmaceutical Salts.
He Y; Ho C; Yang D; Chen J; Orton E
J Pharm Sci; 2017 May; 106(5):1190-1196. PubMed ID: 28153596
[TBL] [Abstract][Full Text] [Related]
10. Polymorph selection: the role of nucleation, crystal growth and molecular modeling.
Erdemir D; Lee AY; Myerson AS
Curr Opin Drug Discov Devel; 2007 Nov; 10(6):746-55. PubMed ID: 17987526
[TBL] [Abstract][Full Text] [Related]
11. Structure, solubility, screening, and synthesis of molecular salts.
Black SN; Collier EA; Davey RJ; Roberts RJ
J Pharm Sci; 2007 May; 96(5):1053-68. PubMed ID: 17455329
[TBL] [Abstract][Full Text] [Related]
12. General principles of pharmaceutical solid polymorphism: a supramolecular perspective.
Rodríguez-Spong B; Price CP; Jayasankar A; Matzger AJ; Rodríguez-Hornedo N
Adv Drug Deliv Rev; 2004 Feb; 56(3):241-74. PubMed ID: 14962581
[TBL] [Abstract][Full Text] [Related]
13. Strategies to address low drug solubility in discovery and development.
Williams HD; Trevaskis NL; Charman SA; Shanker RM; Charman WN; Pouton CW; Porter CJ
Pharmacol Rev; 2013 Jan; 65(1):315-499. PubMed ID: 23383426
[TBL] [Abstract][Full Text] [Related]
14. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
Meng F; Gala U; Chauhan H
Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
[TBL] [Abstract][Full Text] [Related]
15. Crystal polymorphism in chemical process development.
Lee AY; Erdemir D; Myerson AS
Annu Rev Chem Biomol Eng; 2011; 2():259-80. PubMed ID: 22432619
[TBL] [Abstract][Full Text] [Related]
16. An investigation into the influence of counterion on the properties of some amorphous organic salts.
Towler CS; Li T; Wikström H; Remick DM; Sanchez-Felix MV; Taylor LS
Mol Pharm; 2008; 5(6):946-55. PubMed ID: 19434850
[TBL] [Abstract][Full Text] [Related]
17. Use of pharmaceutical salts and cocrystals to address the issue of poor solubility.
Elder DP; Holm R; Diego HL
Int J Pharm; 2013 Aug; 453(1):88-100. PubMed ID: 23182973
[TBL] [Abstract][Full Text] [Related]
18. Analysis of relationships between solid-state properties, counterion, and developability of pharmaceutical salts.
Guerrieri P; Rumondor AC; Li T; Taylor LS
AAPS PharmSciTech; 2010 Sep; 11(3):1212-22. PubMed ID: 20680707
[TBL] [Abstract][Full Text] [Related]
19. Impact of the counterion on the solubility and physicochemical properties of salts of carboxylic acid drugs.
David SE; Timmins P; Conway BR
Drug Dev Ind Pharm; 2012 Jan; 38(1):93-103. PubMed ID: 22118222
[TBL] [Abstract][Full Text] [Related]
20. Solid state amorphization of pharmaceuticals.
Willart JF; Descamps M
Mol Pharm; 2008; 5(6):905-20. PubMed ID: 18954076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
